{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T02:18:28Z","timestamp":1773281908551,"version":"3.50.1"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2015,12,16]],"date-time":"2015-12-16T00:00:00Z","timestamp":1450224000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Mater Sci: Mater Med"],"published-print":{"date-parts":[[2016,1]]},"DOI":"10.1007\/s10856-015-5621-1","type":"journal-article","created":{"date-parts":[[2015,12,16]],"date-time":"2015-12-16T10:59:13Z","timestamp":1450263553000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Anti-Toxoplasma activity and impact evaluation of lyophilization, hot molding process, and gamma-irradiation techniques on CLH-PLGA intravitreal implants"],"prefix":"10.1007","volume":"27","author":[{"given":"Gabriella M.","family":"Fernandes-Cunha","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C\u00edntia M. F.","family":"Rezende","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wagner N.","family":"Mussel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gisele R.","family":"da Silva","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elionai C.","family":"de L. Gomes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria I.","family":"Yoshida","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S\u00edlvia L.","family":"Fialho","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alfredo M.","family":"Goes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dawison A.","family":"Gomes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ricardo W.","family":"de Almeida Vitor","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Armando","family":"Silva-Cunha","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2015,12,16]]},"reference":[{"issue":"1","key":"5621_CR1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1136\/bjo.57.1.1","volume":"57","author":"ES Perkins","year":"1973","unstructured":"Perkins ES. Ocular toxoplasmosis. Br J Ophthalmol. 1973;57(1):1\u201317.","journal-title":"Br J Ophthalmol"},{"key":"5621_CR2","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1136\/bjo.80.4.332","volume":"80","author":"A Rothova","year":"1996","unstructured":"Rothova A, Suttorp-VanSchulten MS, Frits TW, Kijlstra A. Causes and frequency of blindness in patients with intraocular inflammatory disease. Br J Ophthalmol. 1996;80:332\u20136.","journal-title":"Br J Ophthalmol"},{"issue":"3","key":"5621_CR3","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1208\/s12248-010-9183-3","volume":"12","author":"R Gaudana","year":"2010","unstructured":"Gaudana R, Ananthula HK, Parenky A, Mitra AK. Ocular drug delivery. AAPS J. 2010;12(3):348\u201360.","journal-title":"AAPS J"},{"issue":"2","key":"5621_CR4","doi-asserted-by":"crossref","first-page":"47","DOI":"10.5497\/wjp.v2.i2.47","volume":"2","author":"A Patel","year":"2013","unstructured":"Patel A, Cholkar K, Agrahari V, Mitra AK. Ocular drug delivery systems: an overview. World J Pharmacol. 2013;2(2):47\u201364.","journal-title":"World J Pharmacol"},{"key":"5621_CR5","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/S0002-9394(14)74456-3","volume":"115","author":"A Rothova","year":"1993","unstructured":"Rothova A, Meenken C, Buitenhuis HJ, Brinkman CJ, Baarsma GS, Boen-Tan TN, de Jong PT, Klaassen-Broekema N, Schweitzer CM, Timmerman Z. Therapy for ocular toxoplasmosis. Am J Ophthalmol. 1993;115:517\u201323.","journal-title":"Am J Ophthalmol"},{"key":"5621_CR6","doi-asserted-by":"crossref","first-page":"255","DOI":"10.2165\/00003088-199018040-00001","volume":"18","author":"RD Schoenwald","year":"1990","unstructured":"Schoenwald RD. Ocular drug delivery: pharmacokinetic considerations. Clin Pharmacokinet. 1990;18:255\u201369.","journal-title":"Clin Pharmacokinet"},{"key":"5621_CR7","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1023\/A:1006129422690","volume":"22","author":"CE Martinez","year":"1998","unstructured":"Martinez CE, Zhang D, Conway MD, Peyman GA. Successful management of ocular toxoplasmosis during pregnancy using combined intraocular clindamycin and dexamethasone with systemic sulfadiazine. Int Ophthalmol. 1998;22:85\u20138.","journal-title":"Int Ophthalmol"},{"key":"5621_CR8","doi-asserted-by":"crossref","first-page":"183","DOI":"10.3928\/1542-8877-20010501-03","volume":"32","author":"K Kishore","year":"2001","unstructured":"Kishore K, Conway MD, Peyman GA. Intravitreal clindamycin and dexamethasone for toxoplasmic retinochoroiditis. Ophthalmic Surg Lasers. 2001;32:183\u201392.","journal-title":"Ophthalmic Surg Lasers"},{"key":"5621_CR9","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1097\/IAE.0b013e31804b3f0d","volume":"27","author":"L Sobrin","year":"2007","unstructured":"Sobrin L, Kump LI, Fosters CS. Intravitreal clindamycin for toxoplasmosis retinochoroiditis. Retina. 2007;27:952\u20137.","journal-title":"Retina"},{"key":"5621_CR10","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.ophtha.2010.04.020","volume":"118","author":"M Soheilian","year":"2011","unstructured":"Soheilian M, Ramezani A, Azimzadeh A, Sadoughi MM, Dehghan MH, Shahghdami R, Yaseri M, Peyman GA. Randomized trial of intravitreal clindamycin and dexamethasone versus pyrimethamine, sulfadiazine, and prednisolone in treatment of ocular toxoplasmosis. Ophthalmology. 2011;118:134\u201341.","journal-title":"Ophthalmology"},{"key":"5621_CR11","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.jpba.2013.10.025","volume":"89","author":"GM Fernandes-Cunha","year":"2014","unstructured":"Fernandes-Cunha GM, Saliba JB, Siqueira RC, Jorge R, Silva-Cunha A. Determination of triamcinolone acetonide in silicone oil and aqueous humor of vitrectomized rabbits\u2019eyes: application for a pharmacokinetic study with intravitreal triamcinolone acetonide injections (Kenalog\u00ae40). J Pharm Biomed Anal. 2014;89:24\u20137.","journal-title":"J Pharm Biomed Anal"},{"issue":"3","key":"5621_CR12","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1097\/ICU.0b013e328338679a","volume":"21","author":"KM Sampat","year":"2010","unstructured":"Sampat KM, Garg SJ. Complications of intravitreal injections. Curr Opin Ophthalmol. 2010;21(3):178\u201383.","journal-title":"Curr Opin Ophthalmol"},{"key":"5621_CR13","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1016\/j.jconrel.2012.01.019","volume":"161","author":"A Bochot","year":"2012","unstructured":"Bochot A, Fattal E. Liposomes for intravitreal drug delivery: a state of the art. J Control Release. 2012;161:628\u201334.","journal-title":"J Control Release"},{"key":"5621_CR14","doi-asserted-by":"crossref","first-page":"2043","DOI":"10.1007\/s11095-010-0159-x","volume":"27","author":"SS Lee","year":"2010","unstructured":"Lee SS, Hughes P, Ross AD, Robinson MR. Biodegradable implants for sustained drug release in the eye. Pharm Res. 2010;27:2043\u201353.","journal-title":"Pharm Res"},{"key":"5621_CR15","unstructured":"Siqueira RC, dos Santos WF, Scott IU, Messias A, Rosa MN, Fernandes-Cunha GM, Silva-Cunha A, Jorge R (2014) Neuroprotective effects of intravitreal triamcinolone acetonide and dexamethasone implant in rabbit retinas after pars plana vitrectomy and silicone oil injection. Retina 1\u20137."},{"issue":"2","key":"5621_CR16","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1089\/jop.2012.0152","volume":"29","author":"DA Bernards","year":"2013","unstructured":"Bernards DA, Bhisitkul RB, Wynn P, Steedman MR, Lee OT, Wong F, Thoongsuwan S, Desai TA. Ocular biocompatibility and structural integrity of micro and nanostructured poly(caprolactone) films. J Ocul Pharmacol Ther. 2013;29(2):249\u201357.","journal-title":"J Ocul Pharmacol Ther"},{"key":"5621_CR17","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.3390\/polym3031377","volume":"3","author":"HK Makadia","year":"2011","unstructured":"Makadia HK, Siegel SJ. Poly Lactic-co-Glycolic Acid (PLGA) as biodegradable controlled drug delivery carrier. Polymers. 2011;3:1377\u201397.","journal-title":"Polymers"},{"key":"5621_CR18","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/S0168-3659(98)00061-3","volume":"55","author":"T Zhou","year":"1998","unstructured":"Zhou T, Lewis H, Foster RE, Schwendeman SP. Development of a multiple-drug delivery implant for intraocular management of proliferative vitreoretinopathy. J Control Release. 1998;55:281\u201395.","journal-title":"J Control Release"},{"key":"5621_CR19","first-page":"1079","volume":"54","author":"A Garcia","year":"2013","unstructured":"Garcia A, Tully J, Maynor B, Yerxa B. Precisely engineered biodegradable intraocular implants for the sustained release of dexamethasone. Investig Ophthalmol Vis Sci. 2013;54:1079.","journal-title":"Investig Ophthalmol Vis Sci"},{"issue":"1","key":"5621_CR20","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.jconrel.2013.01.007","volume":"167","author":"SR Chennamaneni","year":"2013","unstructured":"Chennamaneni SR, Mamalis C, Archer B, Oakey Z, Ambati BK. Development of a novel bioerodible dexamethasone implant for uveitis and postoperative cataract inflammation. J Control Release. 2013;167(1):53\u20139.","journal-title":"J Control Release"},{"key":"5621_CR21","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1016\/j.jpba.2014.08.023","volume":"102","author":"GM Fernandes-Cunha","year":"2015","unstructured":"Fernandes-Cunha GM, Gouvea DM, Fulgencio GO, Rezende CMF, Silva GR, Bretas JM, Fialho SL, Lopes NP, Silva-Cunha A. Development of a method to quantify clindamycin in vitreous humor of rabbits\u2019 eyes by UPLC-MS\/MS: application to a comparative pharmacokinetic study and in vivo ocular biocompatibility evaluation. J Pharm Biomed Anal. 2015;102:346\u201352.","journal-title":"J Pharm Biomed Anal"},{"issue":"2","key":"5621_CR22","doi-asserted-by":"crossref","first-page":"e16414","DOI":"10.17795\/jjnpp-16414","volume":"9","author":"L Tamaddon","year":"2014","unstructured":"Tamaddon L, Mostafavi A, Riazi-esfahani M, Karkhane R, Aghazadeh S, Rafiee-Tehrani M, Dorkoosh FA, Amoli FA. Development, characterizations and biocompatibility evaluations of intravitreal lipid implants. Jundishapur J Nat Pharm Prod. 2014;9(2):e16414.","journal-title":"Jundishapur J Nat Pharm Prod"},{"issue":"32","key":"5621_CR23","first-page":"1","volume":"4","author":"L Tamaddon","year":"2015","unstructured":"Tamaddon L, Mostafavi SA, Karkhane R, Riazi-Esfahani M, Dorkoosh FA, Rafiee-Tehrani M. Design and development of intraocular polymeric implant systems for long-term controlled-release of clindamycin phosphate for toxoplasmic retinochoroiditis. Adv Biomed Res. 2015;4(32):1\u201322.","journal-title":"Adv Biomed Res"},{"issue":"5","key":"5621_CR24","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1021\/op000023y","volume":"4","author":"SR Chemburkar","year":"2000","unstructured":"Chemburkar SR, Bauer J, Deming K, Spiwek H, Patel K, Morris J, Henry R, Spanton S, Dziki W, Porter W, Quick J, Bauer P, Donaubauer J, Narayanan BA, Soldani M, Riley D, McFarland K. Dealing with the impact of ritonavir polymorphs on the late stages of bulk drug process development. Org Process Res Dev. 2000;4(5):413\u20137.","journal-title":"Org Process Res Dev"},{"key":"5621_CR25","first-page":"9","volume":"74","author":"F Franks","year":"1992","unstructured":"Franks F. Frezee-drying: from empiricism to predictability. The significance of glass transitions. Dev Biol Stand. 1992;74:9\u201319.","journal-title":"Dev Biol Stand"},{"issue":"9","key":"5621_CR26","doi-asserted-by":"crossref","first-page":"857","DOI":"10.3109\/03639049709148693","volume":"23","author":"MB Sintzel","year":"1997","unstructured":"Sintzel MB, Merkli A, Tabatabay C, Gurny R. Influence of irradiation sterilization on polymers used as drug carriers\u2014a review. Drug Dev Ind Pharm. 1997;23(9):857\u201378.","journal-title":"Drug Dev Ind Pharm"},{"issue":"1","key":"5621_CR27","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/S0168-3659(98)00170-9","volume":"59","author":"B Bittner","year":"1999","unstructured":"Bittner B, M\u00e4der K, Kroll C, Borchert HH, Kissel T. Tetracycline-HCl-loaded poly(DL-lactide-co-glycolide) microspheres prepared by a spray drying technique: influence of \u03b3-irradiation on radical formation and polymer degradation. J Control Release. 1999;59(1):23\u201332.","journal-title":"J Control Release"},{"key":"5621_CR28","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1080\/10717540590921432","volume":"12","author":"SL Fialho","year":"2005","unstructured":"Fialho SL, Silva-Cunha A. Manufacturing techniques of biodegradable implants intended to intraocular application. Drug Deliv. 2005;12:109\u201316.","journal-title":"Drug Deliv"},{"key":"5621_CR29","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/0168-583X(88)90191-7","volume":"32","author":"A Chapiro","year":"1988","unstructured":"Chapiro A. Chemical modifications in irradiated polymers. Nucl Instrum Methods Phys Res B. 1988;32:111\u20134.","journal-title":"Nucl Instrum Methods Phys Res B"},{"key":"5621_CR30","unstructured":"Food and Drug Administration( 2000) FDA guidance for industry: analytical procedures and methods validation, U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research, Rockville."},{"key":"5621_CR31","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/0022-1759(83)90303-4","volume":"65","author":"T Mosmann","year":"1983","unstructured":"Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods. 1983;65:55\u201363.","journal-title":"J Immunol Methods"},{"key":"5621_CR32","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1006\/expr.1995.1157","volume":"81","author":"T Tanaka","year":"1995","unstructured":"Tanaka T, Omata Y, Saito A, Shimazaki K, Yamauchi K, Takase M, Kawase K, Igarashi K, Suzuki N. Toxoplasma gondii: parasiticidal effects of bovine lactoferricin against parasites. Exp Parasitol. 1995;81:614\u20137.","journal-title":"Exp Parasitol"},{"issue":"3","key":"5621_CR33","first-page":"3","volume":"1","author":"SS Bharate","year":"2010","unstructured":"Bharate SS, Bharate SB, Bajaj AN. Interactions and incompatibilities of pharmaceutical excipients with active pharmaceutical ingredients: a comprehensive review. J Excip Food Chem. 2010;1(3):3\u201326.","journal-title":"J Excip Food Chem"},{"issue":"2","key":"5621_CR34","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/j.colsurfb.2011.05.023","volume":"87","author":"M Vukomanovi\u0107","year":"2011","unstructured":"Vukomanovi\u0107 M, Zava\u0161nik-Bergant T, Bra\u010dko I, Skapin SD, Ignjatovi\u0107 N, Radmilovi\u0107 V, Uskokovi\u0107 D. Poly(D,L-lactide-co-glycolide)\/hydroxyapatite core-shell nanospheres. Part 3: properties of hydroxyapatite nano-rods and investigation of a distribution of the drug within the composite. Colloids Surf B Biointerfaces. 2011;87(2):226\u201335.","journal-title":"Colloids Surf B Biointerfaces"},{"issue":"1","key":"5621_CR35","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1002\/jps.23358","volume":"102","author":"LA Wegiel","year":"2013","unstructured":"Wegiel LA, Mauer LJ, Edgar KJ, Taylor LS. Crystallization of amorphous solid dispersions of resveratrol during preparation and storage\u2014impact of different polymers. J Pharm Sci. 2013;102(1):171\u201384.","journal-title":"J Pharm Sci"},{"key":"5621_CR36","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.eurpolymj.2014.09.005","volume":"60","author":"I Bonadies","year":"2014","unstructured":"Bonadies I, Ambrogi V, Ascione L, Carfagna CA. A hyperbranched polyester as antinucleating agent for Artemisinin in electrospun nanofibers. Eur Polymer J. 2014;60:145\u201352.","journal-title":"Eur Polymer J"},{"issue":"2","key":"5621_CR37","doi-asserted-by":"crossref","first-page":"E1","DOI":"10.1208\/pt0802037","volume":"8","author":"P Blasi","year":"2007","unstructured":"Blasi P, Schoubben A, Giovagnoli S, Perioli L, Ricci M, Rossi C. Ketoprofen Poly(lactide-co-glycolide) Physical Interaction. AAPS Pharm Sci Tech. 2007;8(2):E1\u20138.","journal-title":"AAPS Pharm Sci Tech"},{"issue":"1","key":"5621_CR38","doi-asserted-by":"crossref","first-page":"50","DOI":"10.4103\/2230-973X.147233","volume":"5","author":"P Patel","year":"2015","unstructured":"Patel P, Patel P. Formulation and evaluation of clindamycin HCL in situgel for vaginal application. Int J Pharm Investig. 2015;5(1):50\u20136.","journal-title":"Int J Pharm Investig"},{"key":"5621_CR39","author":"HS Costa","year":"2012","unstructured":"Costa HS, Mansur AAP, Pereira MM, Mansur HS. Engineered hybrid scaffolds of poly(vinyl alcohol)\/bioactive glass for potential bone engineering applications: synthesis, characterization, cytocompatibility, and degradation. J Nanomater. 2012;. doi: 10.1155\/2012\/718470 .","journal-title":"J Nanomater"},{"key":"5621_CR40","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/0378-5173(94)90072-8","volume":"101","author":"MR Jenquin","year":"1994","unstructured":"Jenquin MR, McGinity JW. Characterization of acrylic resin matrix films and mechanisms of drug-polymer interactions. Int J Pharm. 1994;101:23\u201334.","journal-title":"Int J Pharm"},{"key":"5621_CR41","unstructured":"Evaluation of Medicines for Human Use CHMP Assessment report Ozurdex International Nonproprietary Name: dexamethasone Procedure No: EMEA\/H\/C\/001140."},{"issue":"1","key":"5621_CR42","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/S0014-827X(01)01171-5","volume":"57","author":"S \u00c7ali\u015f","year":"2002","unstructured":"\u00c7ali\u015f S, Bozda\u011f S, Ka\u015f HS, Tuncay M, Hincal AA. Influence of irradiation sterilization on poly(lactide-co-glycolide) microspheres containing anti-inflammatory drugs. II Farmaco. 2002;57(1):55\u201362.","journal-title":"II Farmaco"},{"issue":"3","key":"5621_CR43","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1177\/0091270004272670","volume":"45","author":"JA Wijsman","year":"2005","unstructured":"Wijsman JA, Dekaban GA, Rieder MJ. Differential toxicity of reactive metabolites of clindamycin and sulfonamides in HIV-infected cells: influence of HIV infection on clindamycin toxicity in vitro. J Clin Pharmacol. 2005;45(3):346\u201351.","journal-title":"J Clin Pharmacol"},{"issue":"7","key":"5621_CR44","doi-asserted-by":"crossref","first-page":"1530","DOI":"10.1128\/AAC.39.7.1530","volume":"39","author":"ME Fichera","year":"1995","unstructured":"Fichera ME, Bhopale MK, Roos DS. In vitro assays elucidate peculiar kinetics of clindamycin action against Toxoplasma Gondii. Antimicrob Agents Chemother. 1995;39(7):1530\u20137.","journal-title":"Antimicrob Agents Chemother"},{"issue":"12","key":"5621_CR45","doi-asserted-by":"crossref","first-page":"2571","DOI":"10.1128\/AAC.37.12.2571","volume":"37","author":"J Blais","year":"1993","unstructured":"Blais J, Tardif C, Chamberland S. Effect of clindamycin on intracellular replication, protein synthesis, and infectivity of Toxoplasma gondii. Antimicrob Agents Chemother. 1993;37(12):2571\u20137.","journal-title":"Antimicrob Agents Chemother"},{"issue":"5","key":"5621_CR46","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1128\/AAC.36.5.1091","volume":"36","author":"ER Pfefferkorn","year":"1992","unstructured":"Pfefferkorn ER, Nothnagel RF, Borotz SE. Parasiticidal effect of clindamycin on Toxoplasma gondii grow in culture cells and selection of a drug-resistant mutante. Antimicrob Agents Chemother. 1992;36(5):1091\u20136.","journal-title":"Antimicrob Agents Chemother"}],"container-title":["Journal of Materials Science: Materials in Medicine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10856-015-5621-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10856-015-5621-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10856-015-5621-1","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,29]],"date-time":"2022-05-29T12:31:00Z","timestamp":1653827460000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10856-015-5621-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,12,16]]},"references-count":46,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2016,1]]}},"alternative-id":["5621"],"URL":"https:\/\/doi.org\/10.1007\/s10856-015-5621-1","relation":{},"ISSN":["0957-4530","1573-4838"],"issn-type":[{"value":"0957-4530","type":"print"},{"value":"1573-4838","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,12,16]]},"article-number":"10"}}